Innate immune signaling in the myelodysplastic syndromes.
Myelodysplastic syndromes (MDS) are heterogeneous clonal hematologic malignancies characterized by cytopenias caused by ineffective hematopoiesis and propensity to progress to acute myeloid leukemia. Innate immunity provides immediate protection against pathogens by coordinating activation of signaling pathways in immune cells. Given the prominent role of the innate immune pathway in regulating hematopoiesis, it is not surprising that aberrant signaling of this pathway is associated with hematologic malignancies. Increased activation of the innate immune pathway may contribute to dysregulated hematopoiesis, dysplasia, and clonal expansion in myelodysplastic syndromes.
Starczynowski
Daniel T
DT
Genome Sciences Centre, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada.
Karsan
Aly
A
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D005786:Gene Expression Regulation / Q000276:immunology; D005802:Genes, MHC Class II; D006410:Hematopoiesis / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D007249:Inflammation / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology; D051379:Mice; D035683:MicroRNAs / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000276:immunology*; D011971:Receptors, Immunologic / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology; D051193:Toll-Like Receptors / Q000276:immunology
D016207:Cytokines; D035683:MicroRNAs; D011971:Receptors, Immunologic; D018124:Receptors, Tumor Necrosis Factor; D051193:Toll-Like Receptors